文献速递淋巴瘤

肿瘤负荷、炎症与产品属性决定axi-cel在大B细胞淋巴瘤中的疗效

Tumor burden, inflammation, and product attributes determine outcomes of axicabtagene ciloleucel in large B-cell lymphoma.
PubMed 文献 · Blood Adv · 2020-01-01

ZUMA-1研究显示axi-cel在难治性大B细胞淋巴瘤中持久缓解率高且安全性可控。预设临床协变量未能明确预测疗效;分析发现CAR T细胞快速扩增(与预处理肿瘤负荷匹配、受产品T细胞适应性影响)、输注的CD8和CCR7+CD45RA+ T细胞数量及宿主全身炎症是持久缓解的最显著决定因素。

要点

  • 预处理肿瘤负荷影响CAR T细胞扩增速度,与持久缓解相关。
  • 输注产品中CD8和CCR7+CD45RA+ T细胞数量是疗效决定因素。
  • 宿主全身炎症与疗效和毒性差异相关。

核心结论

  • CAR T细胞快速扩增与预处理肿瘤负荷匹配、输注的CD8和CCR7+CD45RA+ T细胞数量及宿主全身炎症是持久缓解的最显著决定因素。

研究设计与样本

  • ZUMA-1试验(NCT02348216)事后分析,评估难治性大B细胞淋巴瘤患者接受axi-cel的临床协变量和扩展生物标志物。

主要发现

  • 预设临床协变量(ECOG体能状态0 vs 1、年龄、疾病亚型、分期、IPI评分)未清晰预测疗效。
  • 单变量和多变量分析表明CAR T细胞快速扩增、输注CD8和CCR7+CD45RA+ T细胞数量及宿主全身炎症是最显著决定因素。
  • 关键参数与临床疗效和毒性存在差异关联。

临床怎么用

  • 可关注预处理肿瘤负荷、产品T细胞表型及宿主炎症状态以优化CAR T细胞治疗。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

ZUMA-1 demonstrated a high rate of durable response and a manageable safety profile with axicabtagene ciloleucel (axi-cel), an anti-CD19 chimeric antigen receptor (CAR) T-cell therapy, in patients with refractory large B-cell lymphoma. As previously reported, prespecified clinical covariates for secondary end point analysis were not clearly predictive of efficacy; these included Eastern Cooperative Oncology Group performance status (0 vs 1), age, disease subtype, disease stage, and International Prognostic Index score. We interrogated covariates included in the statistical analysis plan and an extensive panel of biomarkers according to an expanded translational biomarker plan. Univariable and multivariable analyses indicated that rapid CAR T-cell expansion commensurate with pretreatment tumor burden (influenced by product T-cell fitness), the number of CD8 and CCR7+CD45RA+ T cells infused, and host systemic inflammation, were the most significant determining factors for durable response. Key parameters differentially associated with clinical efficacy and toxicities, with both theoretical and practical implications for optimizing CAR T-cell therapy. This trial was registered at www.clinicaltrials.gov as #NCT02348216.

来源:Blood Adv,查看原文。版权归原作者所有。

引用

  1. Locke FL, Rossi JM, Neelapu SS, et al. Tumor burden, inflammation, and product attributes determine outcomes of axicabtagene ciloleucel in large B-cell lymphoma. Blood Adv. 2020. PMID: 33035333. doi:10.1182/bloodadvances.2020002394

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。